Reply: Loss-of-Function Mutations to Estimate Pharmacological ANGPTL3 Inhibition

Nathan O. Stitziel; Kiran Musunuru; Sekar Kathiresan

doi:10.1016/j.jacc.2017.07.794

Reply: Loss-of-Function Mutations to Estimate Pharmacological ANGPTL3 Inhibition

Nathan O. Stitziel, Kiran Musunuru, Sekar Kathiresan

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	2099-2100
Number of pages	2
Journal	Journal of the American College of Cardiology
Volume	70
Issue number	16
DOIs	https://doi.org/10.1016/j.jacc.2017.07.794
State	Published - Oct 17 2017

Access to Document

10.1016/j.jacc.2017.07.794

Cite this

@article{1da3a223005e486595684f343f777140,

title = "Reply: Loss-of-Function Mutations to Estimate Pharmacological ANGPTL3 Inhibition",

author = "Stitziel, {Nathan O.} and Kiran Musunuru and Sekar Kathiresan",

note = "Funding Information: Please note: Dr. Stitziel has received a research grant from AstraZeneca and consulting fees from Aegerion Pharmaceuticals. Dr. Kathiresan has received grants from Bayer Healthcare, Aegerion Pharmaceuticals, and Regeneron Pharmaceuticals; has received consulting fees from Merck, Novartis, Sanofi, AstraZeneca, Alnylam Pharmaceuticals, Leerink Partners, Noble Insights, Quest Diagnostics, Genomics PLC, and Eli Lilly; and holds equity in San Therapeutics and Catabasis Pharmaceuticals. Dr. Musunuru has reported that he has no relationships relevant to the contents of this paper to disclose. ",

year = "2017",

month = oct,

day = "17",

doi = "10.1016/j.jacc.2017.07.794",

language = "English",

volume = "70",

pages = "2099--2100",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

number = "16",

}

TY - JOUR

T1 - Reply

T2 - Loss-of-Function Mutations to Estimate Pharmacological ANGPTL3 Inhibition

AU - Stitziel, Nathan O.

AU - Musunuru, Kiran

AU - Kathiresan, Sekar

N1 - Funding Information: Please note: Dr. Stitziel has received a research grant from AstraZeneca and consulting fees from Aegerion Pharmaceuticals. Dr. Kathiresan has received grants from Bayer Healthcare, Aegerion Pharmaceuticals, and Regeneron Pharmaceuticals; has received consulting fees from Merck, Novartis, Sanofi, AstraZeneca, Alnylam Pharmaceuticals, Leerink Partners, Noble Insights, Quest Diagnostics, Genomics PLC, and Eli Lilly; and holds equity in San Therapeutics and Catabasis Pharmaceuticals. Dr. Musunuru has reported that he has no relationships relevant to the contents of this paper to disclose.

PY - 2017/10/17

Y1 - 2017/10/17

UR - http://www.scopus.com/inward/record.url?scp=85032287027&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2017.07.794

DO - 10.1016/j.jacc.2017.07.794

M3 - Letter

C2 - 29025568

AN - SCOPUS:85032287027

SN - 0735-1097

VL - 70

SP - 2099

EP - 2100

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 16

ER -

Reply: Loss-of-Function Mutations to Estimate Pharmacological ANGPTL3 Inhibition

Access to Document

Other files and links

Cite this